ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 4 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,986,366 | -27.3% | 139,870 | -5.9% | 0.15% | -20.3% |
| Q2 2023 | $6,856,948 | +15.0% | 148,644 | -0.0% | 0.19% | +8.7% |
| Q1 2023 | $5,962,349 | +89076.6% | 148,687 | +3.0% | 0.17% | -18.1% |
| Q4 2022 | $6,686 | -99.9% | 144,306 | +21.3% | 0.21% | +31.2% |
| Q3 2022 | $4,925,000 | -34.2% | 118,929 | -5.2% | 0.16% | -29.2% |
| Q2 2022 | $7,488,000 | -17.9% | 125,506 | -0.1% | 0.23% | +4.6% |
| Q1 2022 | $9,121,000 | – | 125,604 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 519,119 | $40,605,000 | 3.00% |
| First Light Asset Management, LLC | 236,958 | $18,535,000 | 2.16% |
| SECTOR GAMMA AS | 108,734 | $8,505,000 | 1.76% |
| Rock Springs Capital Management LP | 646,841 | $50,596,000 | 1.39% |
| Atika Capital Management LLC | 79,000 | $6,180,000 | 0.80% |
| Capital Impact Advisors, LLC | 30,582 | $2,392,000 | 0.80% |
| FEDERATED HERMES, INC. | 4,080,359 | $319,166,000 | 0.79% |
| Rhenman & Partners Asset Management AB | 61,500 | $4,811,000 | 0.52% |
| Ikarian Capital, LLC | 73,500 | $5,749,000 | 0.46% |
| Capital International, Inc./CA/ | 477,858 | $37,378,000 | 0.46% |